×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AKRO – akero therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AKRO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
08:07 am
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Medium
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
11/18
07:28 am
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $65.00 price target on the stock.
Medium
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $65.00 price target on the stock.
11/15
11:11 am
akro
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 [Yahoo! Finance]
Low
Report
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 [Yahoo! Finance]
11/15
11:00 am
akro
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
Low
Report
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
11/13
04:05 pm
akro
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
Medium
Report
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
11/13
02:07 am
akro
Akero Therapeutics Advances in MASH Treatment Trials [Yahoo! Finance]
Medium
Report
Akero Therapeutics Advances in MASH Treatment Trials [Yahoo! Finance]
11/11
02:01 pm
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
11/8
07:00 am
akro
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
09:58 pm
akro
Form 4 Akero Therapeutics, Inc. For: Nov 15 Filed by: Yale Catriona
Low
Report
Form 4 Akero Therapeutics, Inc. For: Nov 15 Filed by: Yale Catriona
11/14
04:00 pm
akro
Form SC 13G/A Akero Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC
Medium
Report
Form SC 13G/A Akero Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC
11/14
01:24 pm
akro
Form SC 13G/A Akero Therapeutics, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G/A Akero Therapeutics, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
06:52 am
akro
Form SC 13G/A Akero Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SC 13G/A Akero Therapeutics, Inc. Filed by: RTW INVESTMENTS, LP
11/13
09:46 am
akro
Form SC 13G/A Akero Therapeutics, Inc. Filed by: ALKEON CAPITAL MANAGEMENT LLC
Medium
Report
Form SC 13G/A Akero Therapeutics, Inc. Filed by: ALKEON CAPITAL MANAGEMENT LLC
11/8
05:06 pm
akro
Form 4 Akero Therapeutics, Inc. For: Nov 06 Filed by: Yale Catriona
Low
Report
Form 4 Akero Therapeutics, Inc. For: Nov 06 Filed by: Yale Catriona
11/8
10:53 am
akro
Form SC 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A Akero Therapeutics, Inc. Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/8
07:31 am
akro
Form 10-Q Akero Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q Akero Therapeutics, Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001
23.4%
4/9 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 15.2%
3/16 Form 10-K Akero Therapeutics, Inc. For: Dec 31 14.7%
6/19 Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Cheng Andrew 13.4%
4/24 Akero Therapeutics (NASDAQ: AKRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock. 13.1%
6/25 Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Harrison Seth Loring 9.7%
12/19 Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P. 7.6%
6/20 Form 424B4 Akero Therapeutics, Inc. 7.5%
4/13 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.5%
4/7 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/9 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 15.2%
3/16 Form 10-K Akero Therapeutics, Inc. For: Dec 31 14.7%
6/19 Form 3 Akero Therapeutics, Inc. For: Jun 19 Filed by: Cheng Andrew 13.4%
4/24 Akero Therapeutics (NASDAQ: AKRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock. 13.1%
6/25 Form 4 Akero Therapeutics, Inc. For: Jun 24 Filed by: Harrison Seth Loring 9.7%
12/19 Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P. 7.6%
6/20 Form 424B4 Akero Therapeutics, Inc. 7.5%
4/13 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.5%
4/7 Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.550 ZacksConsensus -0.580 ActVsEst 0.030 - Beat
-31.4%
1/21 Form 4 Akero Therapeutics, Inc. For: Jan 16 Filed by: Versant Venture Capital VI, L.P. -17.4%
3/18 Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. -14.8%
9/6 Form 8-K Akero Therapeutics, Inc. For: Sep 05 -13.8%
3/6 Form 4 Akero Therapeutics, Inc. For: Mar 04 Filed by: Adelman Robert J -9.7%
12/31 Form 4 Akero Therapeutics, Inc. For: Dec 27 Filed by: Versant Venture Capital VI, L.P. -9.5%
1/2 Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P. -8.7%
3/31 Form 8-K Akero Therapeutics, Inc. For: Mar 31 -7.8%
12/13 Form 4 Akero Therapeutics, Inc. For: Dec 13 Filed by: Rolph Timothy -7.8%
1/14 Form 4 Akero Therapeutics, Inc. For: Jan 13 Filed by: Adelman Robert J -6.0%
1/21 Form 4 Akero Therapeutics, Inc. For: Jan 16 Filed by: Versant Venture Capital VI, L.P. -17.4%
3/18 Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. -14.8%
9/6 Form 8-K Akero Therapeutics, Inc. For: Sep 05 -13.8%
3/6 Form 4 Akero Therapeutics, Inc. For: Mar 04 Filed by: Adelman Robert J -9.7%
12/31 Form 4 Akero Therapeutics, Inc. For: Dec 27 Filed by: Versant Venture Capital VI, L.P. -9.5%
1/2 Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P. -8.7%
3/31 Form 8-K Akero Therapeutics, Inc. For: Mar 31 -7.8%
12/13 Form 4 Akero Therapeutics, Inc. For: Dec 13 Filed by: Rolph Timothy -7.8%
1/14 Form 4 Akero Therapeutics, Inc. For: Jan 13 Filed by: Adelman Robert J -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: